Health-Related Quality of Life after Dengue Fever, Morelos, Mexico, 2016-2017

Annika Schulte, Ingo Weber, Diana Carolina Tiga-Loza, Irma Y Amaya Larios, Donald S Shepard, Cynthia A Tschampl, Eduardo A Undurraga, Ruth A Martínez-Vega, Florian Fischer, Lilia Chihu, Jose Ramos-Castañeda, Annika Schulte, Ingo Weber, Diana Carolina Tiga-Loza, Irma Y Amaya Larios, Donald S Shepard, Cynthia A Tschampl, Eduardo A Undurraga, Ruth A Martínez-Vega, Florian Fischer, Lilia Chihu, Jose Ramos-Castañeda

Abstract

We adapted the EQ-5D-3L questionnaire and visual analog scale to assess health-related quality of life (HRQOL) and persistent symptoms in 79 patients with laboratory-confirmed dengue in Morelos, Mexico. The lowest HRQOLs were 0.53 and 38.1 (febrile phase). Patients recovered baseline HRQOL in ≈2 months.

Keywords: Dengue fever; HRQOL; Mexico; arbovirus infection; arboviruses; burden of disease; dengue virus; economic burden; health status; health-related quality of life; life quality; persistent symptoms; quality of life; vector-borne infections; viruses.

Figures

Figure 1
Figure 1
Average self-reported health status, as measured by a 0–100 EQ-VAS, of patients with laboratory-confirmed dengue during the first week after onset of dengue symptoms (A) and from baseline to 121–180 days (B), Morelos, Mexico, 2016–2017. The EQ-VAS scale measures self-reported health, ranging from 0 (worst health status) to 100 (best health status). EQ-VAS is part of the EQ-5D-3L instrument for measuring health-related quality of life. EQ-VAS, visual analog scale. n values indicate number of patients responding to questionnaire during the indicated day range. Error bars indicate 95% CI.
Figure 2
Figure 2
Average health-related quality of life, as measured by the EQ-5D index score, in patients with laboratory-confirmed dengue during days 1–6 of a dengue fever episode (A) and from baseline to 121–180 days (B), Morelos, Mexico, 2016–2017. The EQ-5D scale is a standardized method for measuring health status. n values indicate number of patients responding to questionnaire during the indicated day range. Error bars indicate 95% CI.

References

    1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504–7. 10.1038/nature12060
    1. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis. 2016;16:935–41. 10.1016/S1473-3099(16)00146-8
    1. Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16:712–23. 10.1016/S1473-3099(16)00026-8
    1. Chan M, Kazatchkine M, Lob-Levyt J, Obaid T, Schweizer J, Sidibe M, et al. Meeting the demand for results and accountability: a call for action on health data from eight global health agencies. PLoS Med. 2010;7:e1000223. 10.1371/journal.pmed.1000223
    1. Hung TM, Clapham HE, Bettis AA, Cuong HQ, Thwaites GE, Wills BA, et al. The estimates of the health and economic burden of dengue in Vietnam. Trends Parasitol. 2018;34:904–18. 10.1016/j.pt.2018.07.007
    1. Tiga DC, Undurraga EA, Ramos-Castañeda J, Martínez-Vega RA, Tschampl CA, Shepard DS. Persistent symptoms of dengue: estimates of the incremental disease and economic burden in Mexico. Am J Trop Med Hyg. 2016;94:1085–9. 10.4269/ajtmh.15-0896
    1. Martelli CMT, Nascimento NE, Suaya JA, Siqueira JB Jr, Souza WV, Turchi MD, et al. Quality of life among adults with confirmed dengue in Brazil. Am J Trop Med Hyg. 2011;85:732–8. 10.4269/ajtmh.2011.11-0067
    1. Lum LCS, Suaya JA, Tan LH, Sah BK, Shepard DS. Quality of life of dengue patients. Am J Trop Med Hyg. 2008;78:862–7. 10.4269/ajtmh.2008.78.862
    1. World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: The Organization; 1997.
    1. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208. 10.1016/0168-8510(90)90421-9
    1. Zarate V, Kind P, Chuang LH. Hispanic valuation of the EQ-5D health states: a social value set for Latin Americans. Value Health. 2008;11:1170–7. 10.1111/j.1524-4733.2008.00349.x
    1. Tran BX, Thu Vu G, Hoang Nguyen L, Tuan Le Nguyen A, Thanh Tran T, Thanh Nguyen B, et al. Cost-of-illness and the health-related quality of life of patients in the dengue fever outbreak in Hanoi in 2017. Int J Environ Res Public Health. 2018;15:1174. 10.3390/ijerph15061174
    1. Suaya JA, Chantha N, Huy R, Sah BK, Moh-Seng C, Socheat D, et al. Clinical characterization, diagnosis and socioeconomic impact of hospitalized dengue in Cambodia [cited 2020 Feb 18].
    1. Armien B, Suaya JA, Quiroz E, Sah BK, Bayard V, Marchena L, et al. Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. Am J Trop Med Hyg. 2008;79:364–71. 10.4269/ajtmh.2008.79.364
    1. Wu S-JL, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med. 2000;6:816–20. 10.1038/77553

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren